MedTrace Logo

Metabolomics of Children With SMA

NCT04587492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-11-10

No results posted yet for this study

Summary

The aim of the proposed project is to evaluate whether the metabolome of patients with spinal muscular atrophy (SMA) before the initiation of treatment with nusinersen differs from the metabolome of healthy individuals and whether it changes 14 months after treatment with nusinersen.

Conditions

Interventions

DRUG

Nusinersen

Treatment with nusinersen

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04587492 on ClinicalTrials.gov